enquiry@goldsteinresearch.com
We established a quick response research team to monitor the impacts of global pandemic COVID19 on this market to keep our clients informed about latest data and changing strategies. The report will incorporate these insight and data factors. | × |
---|
Understand the COVID-19 Outbreak and its impact on global & regional businesses
request free proposal
Insights on a world turned upside down : Re-imagining
The post-COVID19 Business resilience & recovery
How effective strategies and business recovery plans are winning the race
request free proposal
Goldstein Market Intelligence help you navigate through the COVID-19 crisis,
we will provide you most relevant market insights on crisis management,
recovery strategy & business continuity.
2020-09-01
750
Global
Many therapeutic agents are utilized for the pharmacologic management of hypertension and the available antihypertensive agents are generally equally effective in lowering blood pressure however; there may be interpatient variability that can affect the way a patient will respond to one treatment over another. 5 mmHg blood pressure declination can reduce the risk of stroke by 34%, ischaemic heart disease by 21%, and reduce the likelihood of dementia, heart failure, and mortality from cardiovascular disease.
Goldstein Market Intelligence forecast the Hypertension Drugs Market size is set to grow at a CAGR of 1.12% over the forecast period of 2017-2030.
On the basis of analysis, systemic hypertension drug accounted for 85% of global hypertension drugs market owing to enhanced patient awareness results in an early diagnosis of the disease followed by treatment.
According to the report, major driving factor for expansion of hypertension drugs market is the rising geriatric population. According to WHO, globally, 22% of adults aged over 18yrs had increased blood pressure and USA’s CDC (Centre for Disease control &prevention) articulated that 70 million American adults are suffering from high blood pressure with only approximately 52% i.e. half the patient pool had got the condition under control.
Further, the report states that the major challenge is patent expiry and increase in more market players hinders the market of big pharma giants like patent expiries of drugs such as Micardis, Avapro, and Diovan.
Based on geography, North America dominates the hypertension drugs market with almost 42% market share in 2016 due to the launch of new disease-modifying therapies. The immensely large patient pool in Asia, Europe and Africa is in itself a huge hypertension drugs market driver and hold the opportunities for future relevance.
According to our global market study on the basis of extensive primary and secondary research: “One trend is changing lifestyle which is responsible to cause disturbance in systolic and diastolic BP and can increase cardiovascular risk that can be measured by non-pharmacological as well as pharmacological means.”
Hypertension Drugs Market Outlook 2017-2030, has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the global Hypertension Drugs market. The report also includes porter’s five force model, SWOT analysis, company profiling, business strategies of market players and their business models. Global market report also recognizes value chain analysis to understand the cost differentiation to provide competitive advantage to the existing and new entry players.
The report covers the present ground scenario and the future growth prospects of the Hypertension Drugs Market for 2017-2030 along with the total number of blood pressure cases worldwide. We calculated the market size and revenue share on the basis of revenue generated from major players and sales of Hypertension Drugs from major players across the globe.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Impact of COVID-19 Outbreak on “Global Hypertension Drugs Market ”, Manufacturers, Contract Manufacturers Suppliers and Recovery Strategy. A complete detailed chapter of 50-70 pages which includes the data and information focused on impacts of the pandemic on the Global Hypertension Drugs Market . It also showcases the expected recovery schedule and losses in the industry and other various major factors.
Our global Hypertension Drugs Market report comprises of the following companies as the key players in the Hypertension Drugs Market:
Other high-flying vendors in the market are: Symplmed Pharmaceuticals, Takeda Pharmaceuticals, United Therapeutics, Valeant Pharmaceuticals, XOMA, Yuhan, Ono Pharmaceutical, Northern Therapeutics, Mast Therapeutics, Eiger BioPharmaceuticals.
For a full detailed overview, send us the sample request.
We can provide two hour complimentary interaction with our analyst after the purchase of this market report. Details are imparted within the report.
1. Research Methodology |
1.1. Secondary Research |
1.2. Primary Research |
1.3. Data Analyzing & Market Size Estimation |
1.4. Research Design |
1.5. Bottom-Up & Top-Down Approach |
2. Market Environment |
2.1. Global Economic Overview |
2.2. Macroeconomic Outlook |
2.3. Demographic Trends Overview |
2.4. Global Hypertension Cases Prevalence Analysis |
2.5. Global Hypertension Drugs Technology Outlook |
2.6. Global Pharmaceutical Industry Outlook |
3. Industry Structure |
3.1. Target Consumer Group Analysis |
3.2. Target Markets (By Countries) |
3.3. Drugs Research & Development Outlook |
3.4. Competitive Strategies |
3.5. Acquisitions & Divestitures |
3.6. Government Regulatory Framework |
4. Regional Industry Analysis |
4.1. Manufacturing Outlook |
4.2. Revenue Analysis |
4.3. Demand & Supply Analysis |
4.4. Marketing & Distribution |
4.5. Pricing Outlook |
4.6. Trade (Import & Export) Analysis |
5. Executive Summary |
5.1. Market Size (USD Million) |
5.2. Forecast Analysis (2017-2025) |
5.3. Market Share & CAGR (%) |
5.4. Regional Share Distribution (%) |
6. Market Dynamics |
6.1. Growth Drivers |
6.2. Market Restraints |
6.3. Risk Analysis |
6.4. Recent Trends & Developments |
6.5. Opportunities for Market Players |
7. Global Hypertension Drugs Market Segmentation |
7.1. Hypertension Drugs Market By Analysis Basis (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.1.1. Market Share(%) of Hypertension Drugs Market by Analysis Basis |
7.1.2. Systemic Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.1.3. Pulmonary Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.1.4. Market Attractiveness of Hypertension Drugs Market by Analysis Basis |
7.1.5. BPS Analysis of Hypertension Drugs Market by Analysis Basis |
7.2. Hypertension Drugs Market ByTherapy Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.2.1. Market Share(%) of Hypertension DrugsMarket by Therapy Type |
7.2.2. Calcium Channel Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.2.3. Diuretics (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.2.4. Beta Blockers Vasodilators (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.2.5. Angiotensin Converting Enzyme Inhibitor (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.2.6. Alpha Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.2.7. Angiotensin Receptor Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.2.8. Renin Inhibitors (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.2.9. Market Attractiveness of Hypertension DrugsMarket by Therapy Type |
7.2.10. BPS Analysis of Hypertension DrugsMarket by Therapy Type |
7.3. Hypertension DrugsMarket By Region (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024) |
7.3.1. North America Hypertension Drugs Market (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.1. North America Hypertension Drugs Market By Country (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024) |
7.3.1.1.1. U.S. Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.1.2. Canada Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.1.3. Market Attractiveness of Hypertension DrugsMarket by Country |
7.3.1.1.4. BPS Analysis of Hypertension DrugsMarket by Country |
7.3.1.2. North America Hypertension Drugs Market By Analysis Basis (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.2.1. Market Share(%) of Hypertension Drugs Market by Type |
7.3.1.2.2. Systemic Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.2.3. Pulmonary Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.2.4. Market Attractiveness of Hypertension Drugs Market by Analysis Basis |
7.3.1.2.5. BPS Analysis of Hypertension Drugs Market by Analysis Basis |
7.3.1.3. North America Hypertension Drugs Market By Therapy Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.3.1. Market Share(%) of Hypertension Drugs Market by Therapy Type |
7.3.1.3.2. Calcium Channel Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.3.3. Diuretics (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.3.4. Beta Blockers Vasodilators (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.3.5. Angiotensin Converting Enzyme Inhibitor (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.3.6. Alpha Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.3.7. Angiotensin Receptor Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.3.8. Renin Inhibitors (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.1.3.9. Market Attractiveness of Hypertension Drugs Market by Therapy Type |
7.3.1.3.10. BPS Analysis of Hypertension Drugs Market by Therapy Type |
7.3.2. Europe Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.1. Europe Hypertension Drugs MarketBy Country (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024) |
7.3.2.1.1. UK Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.1.2. France Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.1.3. Italy Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.1.4. Germany Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.1.5. Spain Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.1.6. Hungary Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.1.7. Sweden Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.1.8. Russia Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.1.9. Poland Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.1.10. Rest of EuropeHypertension Drugs Market (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.1.11. Market Attractiveness of Hypertension DrugsMarket by Country |
7.3.2.1.12. BPS Analysis of Hypertension DrugsMarket by Country |
7.3.2.2. Europe Hypertension Drugs Market By Analysis Basis (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.2.1. Market Share(%) of Hypertension Drugs Market by Type |
7.3.2.2.2. Systemic Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.2.3. Pulmonary Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.2.4. Market Attractiveness of Hypertension Drugs Market by Analysis Basis |
7.3.2.2.5. BPS Analysis of Hypertension Drugs Market by Analysis Basis |
7.3.2.3. Europe Hypertension Drugs Market By Therapy Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.3.1. Market Share(%) of Hypertension Drugs Market by Therapy Type |
7.3.2.3.2. Calcium Channel Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.3.3. Diuretics (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.3.4. Beta Blockers Vasodilators (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.3.5. Angiotensin Converting Enzyme Inhibitor (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.3.6. Alpha Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.3.7. Angiotensin Receptor Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.3.8. Renin Inhibitors (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.2.3.9. Market Attractiveness of Hypertension Drugs Market by Therapy Type |
7.3.2.3.10. BPS Analysis of Hypertension Drugs Market by Therapy Type |
7.3.3. Middle East & Africa Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.1. Middle East & Africa Hypertension DrugsMarket By Country (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024) |
7.3.3.1.1. Gulf Cooperation Council Countries (GCC) Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.1.2. South Africa Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.1.3. North Africa Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.1.4. Rest of Middle East and Africa Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.1.5. Market Attractiveness of Hypertension DrugsMarket by Country |
7.3.3.1.6. BPS Analysis of Hypertension DrugsMarket by Country |
7.3.3.2. Middle East & Africa Hypertension Drugs Market By Analysis Basis (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.2.1. Market Share(%) of Hypertension Drugs Market by Type |
7.3.3.2.2. Systemic Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.2.3. Pulmonary Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.2.4. Market Attractiveness of Hypertension Drugs Market by Analysis Basis |
7.3.3.2.5. BPS Analysis of Hypertension Drugs Market by Analysis Basis |
7.3.3.3. Middle East & Africa Hypertension Drugs Market By Therapy Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.3.1. Market Share(%) of Hypertension Drugs Market by Therapy Type |
7.3.3.3.2. Calcium Channel Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.3.3. Diuretics (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.3.4. Beta Blockers Vasodilators (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.3.5. Angiotensin Converting Enzyme Inhibitor (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.3.6. Alpha Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.3.7. Angiotensin Receptor Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.3.8. Renin Inhibitors (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.3.3.9. Market Attractiveness of Hypertension Drugs Market by Therapy Type |
7.3.3.3.10. BPS Analysis of Hypertension Drugs Market by Therapy Type |
7.3.4. Latin America Hypertension Drugs Market (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.1. Latin America Hypertension DrugsBy Country (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024) |
7.3.4.1.1. Brazil Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.1.2. Mexico Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.1.3. Rest of Latin America Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.1.4. Market Attractiveness of Hypertension DrugsMarket by Country |
7.3.4.1.5. BPS Analysis of Hypertension DrugsMarket by Country |
7.3.4.2. Latin America Hypertension Drugs Market By Analysis Basis (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.2.1. Market Share(%) of Hypertension Drugs Market by Type |
7.3.4.2.2. Systemic Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.2.3. Pulmonary Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.2.4. Market Attractiveness of Hypertension Drugs Market by Analysis Basis |
7.3.4.2.5. BPS Analysis of Hypertension Drugs Market by Analysis Basis |
7.3.4.3. Latin America Hypertension Drugs Market By Therapy Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.3.1. Market Share(%) of Hypertension Drugs Market by Therapy Type |
7.3.4.3.2. Calcium Channel Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.3.3. Diuretics (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.3.4. Beta Blockers Vasodilators (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.3.5. Angiotensin Converting Enzyme Inhibitor (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.3.6. Alpha Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.3.7. Angiotensin Receptor Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.3.8. Renin Inhibitors (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.4.3.9. Market Attractiveness of Hypertension Drugs Market by Therapy Type |
7.3.4.3.10. BPS Analysis of Hypertension Drugs Market by Therapy Type |
7.3.5. Asia Pacific (APAC) Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.1. Asia Pacific Hypertension DrugsMarket By Country (Market Share (%) & Y-o-Y Growth Comparison, 2016-2024) |
7.3.5.1.1. China Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.1.2. Japan Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.1.3. India Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.1.4. Singapore Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.1.5. South Korea Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.1.6. Australia Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.1.7. New Zealand Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.1.8. Rest of APAC Hypertension DrugsMarket (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.1.9. Market Attractiveness of Hypertension DrugsMarket by Country |
7.3.5.1.10. BPS Analysis of Hypertension DrugsMarket by Country |
7.3.5.2. Asia Pacific Hypertension Drugs Market By Analysis Basis (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.2.1. Market Share(%) of Hypertension Drugs Market by Type |
7.3.5.2.2. Systemic Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.2.3. Pulmonary Hypertension Drugs (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.2.4. Market Attractiveness of Hypertension Drugs Market by Analysis Basis |
7.3.5.2.5. BPS Analysis of Hypertension Drugs Market by Analysis Basis |
7.3.5.3. Asia Pacific Hypertension Drugs Market By Therapy Type (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.3.1. Market Share(%) of Hypertension Drugs Market by Therapy Type |
7.3.5.3.2. Calcium Channel Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.3.3. Diuretics (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.3.4. Beta Blockers Vasodilators (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.3.5. Angiotensin Converting Enzyme Inhibitor (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.3.6. Alpha Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.3.7. Angiotensin Receptor Blockers (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.3.8. Renin Inhibitors (Market Size ($ Billion) & Y-o-Y Growth Analysis, 2016-2024) |
7.3.5.3.9. Market Attractiveness of Hypertension Drugs Market by Therapy Type |
7.3.5.3.10. BPS Analysis of Hypertension Drugs Market by Therapy Type |
8. Competitive Outlook |
8.1. Market Share of Major Players |
8.2. Company Profiles |
8.2.1. Novartis AG |
8.2.1.1. Company Synopsis |
8.2.1.2. Business Strategy |
8.2.1.3. Product Portfolio |
8.2.1.4. SWOT Analysis |
8.2.2. Lupin Limited |
8.2.3. Sun Pharmaceuticals LLC |
8.2.4. Daiichi – Sankyo |
8.2.5. Pfizer Inc. |
8.2.6. Sanofi S.A |
8.2.7. AstraZeneca Plc. |
8.2.8. Johnson & Johnson Ltd. |
8.2.9. BoehringerIngelheim |
8.2.10. Merck & Co |
8.2.11. Roche |
8.2.12. Abbott |
8.2.13. GlaxoSmithKline plc. |
8.2.14. AstraZeneca |
8.2.15. Bayer AG |
8.2.16. Gilead |
8.2.17. Actelion |
9. Porter’s Five Force Model |
10. Market Landscape: Competition and Beyond |
11. Market outlook for business players and entry level players to ascertain their business in dynamic ecosystem |
12. Expert Analysis |
13. Concluding Remarks |
A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements
OR Call Us:+1-646-568-7747Global Powder Dietary Supplements Market Outlook 2030: By Product Type, By Ingredients Type, By End Users, By Distribution Channels, By Geography With COVID-19 impact | Forecast Period 2017-2030
Global Brain Health Supplements Market Report 2030: By Ingredients, By Applications, By Supplements Form, By Distribution Channels, By End Users, By Geography With COVID-19 impact | Forecast Period 2017-2030
Australia Stress Management Supplements Market : By Supplement, By Nature. By Distribution Channel, With COVID-19 impact | Forecast Period 2017-2030
Europe Stress Management Supplements Market: Industry Trends, Manufactures, Demand, Key Players, Drivers, Restraints, Y-O-Y Growth Rate, Scope, Revenue Chart With COVID-19 impact | Forecast Period 2017-2030
Global Stress Management/Relief Supplements Market Report- Trends, share, Key Players, Manufacturer's list, Trade Data, Industry Analysis, By Supplement(Tryptophan, Zinc, Magnesium, Vitamin B, Iron Supplement), By Nature(Herbal & Chemical Based), By Distribution Channel With COVID-19 impact | Forecast Period 2017-2030